Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$4.52
+1.3%		$4.86
$3.63
▼
$8.98
$168.82M1.08135,679 shs121,510 shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$5.51
-13.6%		$7.32
$4.91
▼
$15.09
$634.47M0.982.31 million shs2.11 million shs
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$4.67
-3.3%		$4.48
$3.67
▼
$23.20
$657.87M1.95.04 million shs3.73 million shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$11.89
-2.0%		$12.25
$7.16
▼
$15.03
$720.33M0.911.46 million shs924,661 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
+1.35%-4.44%-2.59%-8.32%-37.57%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-13.64%-9.67%-13.36%-30.60%-62.26%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-3.31%-0.64%+10.14%-11.72%-55.94%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-1.98%+6.35%-4.50%+18.54%+28.13%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$4.52
+1.3%		$4.86
$3.63
▼
$8.98
$168.82M1.08135,679 shs121,510 shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$5.51
-13.6%		$7.32
$4.91
▼
$15.09
$634.47M0.982.31 million shs2.11 million shs
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$4.67
-3.3%		$4.48
$3.67
▼
$23.20
$657.87M1.95.04 million shs3.73 million shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$11.89
-2.0%		$12.25
$7.16
▼
$15.03
$720.33M0.911.46 million shs924,661 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
+1.35%-4.44%-2.59%-8.32%-37.57%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-13.64%-9.67%-13.36%-30.60%-62.26%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-3.31%-0.64%+10.14%-11.72%-55.94%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-1.98%+6.35%-4.50%+18.54%+28.13%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
2.00
Hold$6.5043.81% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2.50
Moderate Buy$28.20411.80% Upside
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2.50
Moderate Buy$11.00135.55% Upside
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.90
Moderate Buy$27.14128.28% Upside

Current Analyst Ratings Breakdown

Latest LFCR, ZVRA, TLRY, and SPRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/20/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$26.00
8/19/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
8/17/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/7/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/7/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$24.00 ➝ $23.00
8/6/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/6/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$25.00 ➝ $28.00
8/4/2026
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/31/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
TD Securities logo
TD Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/29/2026
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$128.87M1.33N/AN/A($0.90) per share-5.02
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$84.28M6.50N/AN/A$0.13 per share42.38
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$210.48M3.02N/AN/A$13.68 per share0.34
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$106.47M6.63$0.93 per share12.82$3.67 per share3.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/A-$1.07N/AN/AN/A-29.93%N/A-16.16%10/2/2026 (Estimated)
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$171.30M-$2.18N/AN/AN/A-184.24%-256.67%-69.63%11/9/2026 (Estimated)
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$121.40M-$1.08N/AN/AN/A-13.11%-7.76%-5.59%10/8/2026 (Estimated)
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$83.23M$0.9212.9214.15N/A42.82%54.54%34.15%11/4/2026 (Estimated)

Latest LFCR, ZVRA, TLRY, and SPRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.4777-$0.63-$0.1523-$0.63$31.32 million$33.66 million
8/5/2026Q2 2026
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$0.19-$0.19N/A-$0.19$34.18 million$34.17 million
8/5/2026Q2 2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$0.11$0.25+$0.14$0.14$33.88 million$39.66 million
7/28/2026Q4 2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$0.0120-$0.43-$0.4180-$0.43$246.30 million$281.71 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/A
3.87
2.69
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
13.72
3.48
3.28
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.22
2.21
1.37
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/A
5.17
5.12

Institutional Ownership

CompanyInstitutional Ownership
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
83.36%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
9.35%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
35.03%

Insider Ownership

CompanyInsider Ownership
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
32.68%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.80%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.84%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
69037.85 million25.48 millionOptionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
9099.45 million65.83 millionOptionable
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
3,595136.20 million135.06 millionOptionable
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2059.38 million57.19 millionOptionable

Recent News About These Companies

Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright
August 20 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zevra-therapeutics-nasdaqzvra-receives-buy-rating-from-hc-wainwright-2026-08-20/
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Rating of "Moderate Buy" from Analysts
August 19 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30969341
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages
August 19 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zevra-therapeutics-inc-nasdaqzvra-given-average-rating-of-moderate-buy-by-brokerages-2026-08-19/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
August 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-zevra-therapeutics-inc---zvra-302850515.html
Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zevra-therapeutics-nasdaqzvra-director-sells-13837500-in-stock-2026-08-12/
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-acquires-400336-shares-of-zevra-therapeutics-inc-zvra-2026-08-12/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
August 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/11/3343243/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-zevra-therapeutics-inc-zvra.html
Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hennion-walsh-asset-management-inc-grows-stock-position-in-zevra-therapeutics-inc-zvra-2026-08-10/
Equities Analysts Offer Predictions for ZVRA FY2027 Earnings
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951802
HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-positive-outlook-for-zvra-fy2027-earnings-2026-08-10/
Guggenheim Cuts Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $23.00
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951495
What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/could-zevra-therapeutics-zvra-npc-051257101.html
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zevra-therapeutics-nasdaqzvra-price-target-lowered-to-2300-at-guggenheim-2026-08-07/
FY2026 EPS Forecast for Zevra Therapeutics Raised by Analyst
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/fy2026-eps-forecast-for-zevra-therapeutics-raised-by-analyst-2026-08-07/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
August 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-zevra-therapeutics-inc---zvra-302845590.html
Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 14.1% on Better-Than-Expected Earnings
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zevra-therapeutics-nasdaqzvra-stock-price-up-141-on-better-than-expected-earnings-2026-08-06/
Citizens Jmp Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/citizens-jmp-forecasts-strong-price-appreciation-for-zevra-therapeutics-nasdaqzvra-stock-2026-08-06/
Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4627136-zevra-outlines-chmp-reexamination-timing-with-q4-opinion-expected-as-miplyffa-orange-book
Zevra Therapeutics Q2 Earnings Call Highlights
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zevra-therapeutics-q2-earnings-call-highlights-2026-08-06/
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931371-zevra-therapeutics-inc-zvra-q2-2026-earnings-call-transcript
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
August 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2969401/zevra-therapeutics-zvra-q2-earnings-and-revenues-surpass-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2969401

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lifecore Biomedical stock logo

Lifecore Biomedical NASDAQ:LFCR

$4.52 +0.06 (+1.35%)
As of 08/20/2026 04:00 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$5.51 -0.87 (-13.64%)
Closing price 08/20/2026 04:00 PM Eastern
Extended Trading
$5.60 +0.09 (+1.63%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Tilray Brands stock logo

Tilray Brands NASDAQ:TLRY

$4.67 -0.16 (-3.31%)
Closing price 08/20/2026 04:00 PM Eastern
Extended Trading
$4.71 +0.04 (+0.84%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

Zevra Therapeutics stock logo

Zevra Therapeutics NASDAQ:ZVRA

$11.89 -0.24 (-1.98%)
Closing price 08/20/2026 04:00 PM Eastern
Extended Trading
$11.89 0.00 (0.00%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas